Erythromycin Lactobionate Intravenous

País: Nova Zelanda

Idioma: anglès

Font: Medsafe (Medicines Safety Authority)

ingredients actius:

Erythromycin lactobionate 300mg;  

Disponible des:

Hospira NZ Ltd

Designació comuna internacional (DCI):

Erythromycin lactobionate 300 mg

Dosis:

300 mg

formulario farmacéutico:

Powder for injection

Composición:

Active: Erythromycin lactobionate 300mg  

Unidades en paquete:

Vial, glass, single dose, 5 x 300mg, 1.5 g

clase:

Prescription

tipo de receta:

Prescription

Fabricat per:

Sandoz Industrial Products SpA

Resumen del producto:

Package - Contents - Shelf Life: Vial, glass, single dose, 5 x 300mg - 1.5 g - 24 months from date of manufacture stored at or below 25°C 24 hours reconstituted stored at or below 25°C 14 days reconstituted stored at 2° to 8°C (Refrigerate, do not freeze)

Data d'autorització:

1990-08-13

Fitxa tècnica

Data Sheet – New Zealand 

Hosp 1.0 
                 1 

ERYTHROMYCIN LACTOBIONATE INTRAVENOUS 

DESCRIPTION 
Erythromycin is a macrolide antibiotic produced by the growth of
certain strains of _Streptomyces _
_erythreus_. Erythromycin Lactobionate is produced
by the combination of erythromycin and lactobionic 
acid. 

PHARMACOLOGY 
The mode of action of erythromycin has been well characterised
as erythromycin binds to the ribosomes 
of bacteria to inhibit protein synthesis without
affecting nucleic acid synthesis. Erythromycin selectively 
binds only to the ribosomes of bacteria but not to the
cytoplasmic ribosomes of the host cells. This highly 
specific interaction of erythromycin with bacterial ribosomes is a
possible explanation for the low toxicity 
and exceptional clinical safety record of erythromycin. 

Erythromycin diffuses readily into most body fluids, except the
cerebrospinal fluid. However in cases of 
meningeal inflammation, higher concentrations are apparent. 

The apparent volume of distribution of erythromycin is around
45% of body weight in normal subjects. 
This large distribution volume is consistent with the extensive
tissue penetration of erythromycin. 

In the presence of normal hepatic function, erythromycin
is concentrated in the liver and excreted in the 
bile; the effect of hepatic dysfunction on excretion
of erythromycin by the liver is not known. 

Between 12% to 15% of intravenously administered erythromycin is
excreted in active form in the urine. 

The drug is also excreted in the faeces. 

The plasma elimination half-life in patients with normal renal
function is about 2 hours. In severe renal 
impairment the half-life may be prolonged to between 4 and 7 hours. 

MICROBIOLOGY: Erythromycin is bacteriostatic and bactericidal
depending on its concentration and the type 
of organism. It inhibits prote